Skip to content

Frequency of SARS COVID-19 Infection Among Malignant Patients at South Egypt Cancer Institute

Frequency of SARS COV-2 Infection Among Malignant Patients at South Egypt Cancer Institute

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05465759
Enrollment
200
Registered
2022-07-20
Start date
2022-07-31
Completion date
2023-08-31
Last updated
2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Assessment the frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute

Detailed description

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age Cancer is one of the most common examples of immunocompromised states

Interventions

OTHERdisease

Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Malignant patients. * PCR positive for covid-19

Exclusion criteria

* PCR negative for covid-19

Design outcomes

Primary

MeasureTime frameDescription
calculate the frequency of SARS-CoV-2 infection among patients with malignant data collection during the study period1 yearTo calculate the rate of SARS-CoV-2 infection among patients with malignant data collection within covid-19 pandemic either retrospective or prospective. Data will include : patient demography such as Age,sex,smoking status,cancer type cancer treatment (patient on chemotherapy or radiotherapy if available), symptoms, signs and laboratory parameters of COVID -19. outcome including hospitalization or ICU admission and mortality rate will be recorded

Contacts

Primary Contactmahmoud ahmed agamy, post graduate
mahmoudahmedatm@gmail.com01017989744

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026